KaliVir Immunotherapeutics is recruiting patients for a PHASE1 clinical trial testing pembrolizumab (Keytruda) for mesothelioma.
The trial, designated NCT06444815, aims to enroll up to 60 participants at 7 sites, including locations in California, Florida, Indiana.
About the Study
VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injection into tumor(s) (called an intratumoral injection) or when given intravenously (into the vein) both alone and in combination with pembrolizumab in patients with solid tumors (STEALTH-001).
Treatment Approach
This trial uses a PD-1 checkpoint inhibitor that helps the immune system recognize and attack cancer cells.
Key trial details:
- Phase: PHASE1
- Sponsor: KaliVir Immunotherapeutics
- Enrollment target: 60
- Status: RECRUITING
Why This Trial Matters
Study Locations
The trial is recruiting at:
- USC/Norris Comprehensive Cancer Center, California
- UC Irvine Health, California
- University of Miami, Florida
- Community Health Network, Indiana
- UPMC- Hillman Cancer Center, Pennsylvania
How to Enroll
Patients interested in this trial should:
- Discuss eligibility with their oncologist
- Review the full eligibility criteria on ClinicalTrials.gov
- Contact the study coordinator for screening